Brief: Lantheus Acquires Global Rights To Life Molecular Imaging’S Novel Therapeutic And Diagnostic Pair
27/06/2024 12:12
June 27 (Reuters) - Lantheus Holdings Inc LNTH.O :
* LANTHEUS ACQUIRES GLOBAL RIGHTS TO LIFE MOLECULAR
IMAGING’S
NOVEL THERAPEUTIC AND DIAGNOSTIC PAIR TARGETING GRPR FOR
PROSTATE AND BREAST CANCERS
* LANTHEUS HOLDINGS INC - TO BEGIN PHASE 1/2A STUDY WITH
(177)LU-DOTA-RM2 IN 2025
Source text for Eikon: ID:nGNX1qVp3x
Further company coverage: LNTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantheus Holdings
See all newsStreet View: Lantheus' tumor kit setback seen as temporary, with growth catalysts still ahead
Brief: Lantheus Receives Complete Response Letter From FDA For Lnth-2501 (Ga 68 Edotreotide)
US FDA declines Lantheus’ tumor imaging kit over third-party manufacturing issues (updated)
US FDA declines to approve Lantheus’ tumor imaging kit
$7 billion could be a 'light' price tag for Lantheus, Truist analysts say